The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84).

In hypoparathyroidism, plasma parathyroid hormone (PTH) levels are inadequate to maintain plasma calcium concentration within the reference range.

The researchers aimed to study the effects of PTH-replacement therapy (PTH-RT) on calcium-phosphate homeostasis and BMD.

Who Took Part

The abstract describes 62 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

Some patients received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.

The methods mention a period of 24 weeks.

What Was Measured

In hypoparathyroidism, plasma parathyroid hormone (PTH) levels are inadequate to maintain plasma calcium concentration within the reference range.

PubMed files the paper under topics including Ascorbic Acid, Bone Density, Calcium, Homeostasis, Hypoparathyroidism, Parathyroid Hormone and Phosphorus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 62 patients over 24 weeks.

The publication is from 2011 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.